$ALNY News
Last published 1d ago
- 1d agoALNYAlnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLDBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in p ...
- 2d agoALNYAlnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CMBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year o ...
- 1w agoALNYAlnylam Pharmaceuticals Q3 Earnings Conference Call - ALNYLAM PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone. Thank you for joining us, and welcome to the Alnylam Pharmaceuticals Q3 Earnings Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a qu
- 1w agoALNYALNYLAM PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoALNYAlnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period ProgressBusiness Wire− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) – − Expands
- 2w agoALNYRNAi Roundtable: HTT02 - ALNYLAM PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone, and welcome to this RNAi Roundtable. We're happy you were able to join us. I'd now like to pass the call over to the company. Good morning, everyone. Thank you for joining us for today's RNAi roundtable,
- 2w agoALNYAlnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s DiseaseBusiness Wire- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice
- 3w agoALNYAlnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial ResultsBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026,
- 1mo agoALNYAMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CMBusiness Wire– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis – – ‘Play by Play’ Uses Sports to Highlight the
- 1mo agoALNYRNAi Roundtable: Zilebesiran - ALNYLAM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone. I'm Kelly Cronin, Senior Manager of Investor Relations at Alnylam, and I'm pleased to welcome you to the second event of Alnyalam's 10th RNAi Roundtable Series. Through this series, we aim to brin
- 1mo agoALNYAlnylam Pharmaceuticals - Morgan Stanley 24th Annual Global Healthcare Conference - ALNYLAM PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from Alnylam Pharmace
- 2mo agoALNYALNYLAM PHARMACEUTICALS INC - ALNYLAM PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good morning, everyone. Thanks for joining us for our next session. My name is Derek Archilla. I'm one of the senior biotech analysts here at Wells. With us today is Al Nilem, Harnasuticals. And from the compa
- 2mo agoALNYAlnylam to Webcast Presentations at Upcoming September Investor ConferencesBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st
- 2mo agoALNYAlnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment SettingsBusiness Wire– Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without
- 2mo agoALNYAlnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026Business WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
- 3mo agoALNYAlnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period ProgressBusiness Wire− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) – − Revises
- 3mo agoALNYAlnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial ResultsBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before
- 3mo agoALNYAlnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological DiseaseBusiness Wire− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) − − Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral
- 4mo agoAZN-GBALNYXBIAstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?CNBCFor years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
- 4mo agoALNYRNAi Roundtable: ALN-6400, Targeting Plasminogen to Address Rare Bleeding Disorders - Alnylam Pharmaceuticals, Inc.Earnings Call TranscriptsGood morning, everyone. I'm Chris Brickley, Director of Investor Relations at Alnylam, and I'm pleased to be kicking off our 10th RNAi Roundtable series this morning. Throughout these events, we aim to highlight a few of
- 4mo agoALNYKomodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence PlatformBusiness WireExpanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences Komodo also unveils new Marmot capabilities to move organizations
- 5mo agoALNYAlnylam to Host Tenth "RNAi Roundtable" Webcast SeriesBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of "RNAi Roundtable" webinars over the coming months. The series will offer
- 5mo agoALNYGoldman Sachs 47th Annual Global Healthcare Conference - Alnylam PharmaceuticalsEarnings Call TranscriptsGreat. Good morning. Thank you, everyone, for joining us. It's a pleasure to have with us the El Nilem team. With us is Jeff Poulton, CFO and Pushkul Garg, Head of Development. Maybe to start here, could you lay out your
- 5mo agoALNYAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi TherapeuticsBusiness Wire− Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam's RNAi platform and 20+ years of proprietary data with Inceptive's foundation models and AI expertise to catalyze
- 5mo agoVRTXALNYBEAMSANAAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumPR NewswireCell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer...
- 5mo agoALNYAlnylam Issues 2025 Corporate Responsibility ReportBusiness Wire– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi
- 6mo agoALNY2026 GLOBAL HEALTHCARE CONFERENCE - Alnylam Pharmaceuticals IncEarnings Call TranscriptsOkay, guys. Thank you for joining us at the Bank of America Healthcare Conference. Good morning. I'm Tizina Mott. I am one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company
- 6mo agoALNYNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease BurdenBusiness Wire− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – − Pooled Analysis of Over 25,000
- 6mo agoALNYAlnylam to Webcast Presentations at Upcoming Investor ConferencesBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities
- 6mo agoALNYAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary
- 6mo agoALNYAlnylam Pharmaceuticals Q1 Earnings Conference Call - Alnylam PharmaceuticalsEarnings Call TranscriptsHello, and thank you for standing by. My name is Ian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Al Nilem Pharmaceuticals Q1 Earnings Conference Call. All lines ha
- 6mo agoALNYAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressBusiness Wire− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025) – −
- 6mo agoALNYARCTDNLIOTLC+1When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechGlobeNewswireAUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector
- 6mo agoALNYAlnylam to Webcast Conference Call Discussing First Quarter 2026 Financial ResultsBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before
- 7mo agoALNYNew Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension ManagementBusiness Wire− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger – − Findings
- 7mo agoALNYAlnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart AssociationBusiness Wire− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30 am ET – Alnylam Pharmaceuticals, Inc.
- 8mo agoALNYAlnylam to Webcast TTR Investor WebinarBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company's website,
- 8mo agoALNYTNYATenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease TherapeuticsGlobeNewswireAgreement Combines Tenaya's Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront
- 8mo agoALNYAlnylam to Webcast Presentation at TD Cowen 46th Annual Health Care ConferenceBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2,
- 9mo agoALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period ProgressBusiness Wire− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and
- 9mo agoALNYAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February
- 10mo agoALNYAlnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi TherapeuticsBusiness WireNew platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam's enzymatic ligation manufacturing platform
- 11mo agoALNYBIIBCDWFER+9Annual Changes to the Nasdaq-100 Index®GlobeNewswireNEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on
- 11mo agoALNYAlnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027Business WireAlnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its
- 11mo agoALNYAlnylam Pharmaceuticals Announces Changes to Board of DirectorsBusiness Wire– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced changes
- 1y agoALNYNew Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CMBusiness Wire− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile – − Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate
- 1y agoALNYAlnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period ProgressBusiness Wire− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – − Continued Broad Access
- 1y agoALNYAlnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial ResultsBusiness WireAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025,
- 1y agoALNYCardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM IntelligencePR NewswireThe cardiovascular drugs market was valued at US$ 174.6 billion in 2024 and is projected to reach US$ 247.8 billion by 2033, achieving a CAGR of 4.0% ...
- 1y agoALNYAlnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of ZilebesiranBusiness Wire- Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment - - Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension